RANI Earnings

RANI reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of against an estimate of 10.00M, resulting in a 0% surprise. The EPS was -0.12, surpassing the expected -0.09 by -33.33%. The stock experienced a -11.01% price change on the earnings day and a -6.61% change over the next five days, reflecting market reactions to the results.

Following RANI's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -11.01% on the day of the release. Over the subsequent five days, it saw a -6.61% change. Historically, RANI's stock price tends to shift by an average of 15.13% in the 10 days leading up to earnings and -3.5% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate RANI's annual revenue to reach 2.25M, while the EPS is projected at -0.14. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between RANI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RANI's stock price typically moves by 15.13% in the 10 days before its earnings and -3.5% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.14 and revenue of 2.25M.

The earnings call reveals positive developments, such as a potential expansion of the Chugai partnership and increased cash reserves. Despite regulatory and strategic risks, cost containment has improved financial health, reducing net losses. The Q&A highlights the RaniPill's potential in the obesity market, with promising Phase I study outcomes that could enhance partnerships. These factors suggest a positive stock price movement, although competitive pressures and execution risks remain.